Swiss pharmaceutical firm Novartis has launched a groundbreaking research study for people with multiple sclerosis (MS) that collects data remotely via their smartphone.

Named elevateMS, this study has been designed to collect sensor-based data relating to physical tasks and symptoms.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The aims are to improve understanding of the daily challenges of MS sufferers, and to discover new ways of measuring treatment effectiveness through real-time data collection.

An Apple a day…

The study uses a mobile application built on Apple’s ResearchKit platform, software that is already in use at companies such as GlaxoSmithKline and Celgene.

The app allows participants to contribute to research from home or on the go, with minimal disruption.

See Also:

At the same time, it provides more accurate data of the patient’s everyday environment and reduces the need for clinical visits.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

By using smartphones, the elevateMS application will capture participant responses to questionnaires, passive and active sensor-based movement data, and data on functional performance tasks completed by the participants.

Designed with patients

The mobile app was designed with input from patients, neurologists, and MS advocates. Patients were consulted on the app’s user interface, what the study should measure, and how the app should track patient activity and disease symptoms.

Doctor and medical director of the Providence Multiple Sclerosis Center Stanley Cohan said: “As physicians, we always want to know how our patients with MS are doing on the treatments we prescribe.

“With the elevateMS app, study participants can frequently document their symptoms in a personal health story. In turn, this data may provide researchers with new ways to look at disease progression and treatment effectiveness."

MS is a chronic and progressive disease affecting around 400,000 people in the US. Novartis is a leader in MS with three approved medications and additional investigational therapies in early and late phases of development.

Sources

http://www.elevatems.org/

http://www.pmlive.com/blogs/digital_intelligence/archive/2017/august/novartis_trial_marks_researchkit_first_in_ms_1202815#

Novartis launches first smartphone-enabled study in MS